Olema Oncology Announces Interim Results From Phase 1b/2 Palazestrant Study, Says 85% Clinical Benefit Rate Observed To Date Across All CBR-Eligible Patients
Portfolio Pulse from Benzinga Newsdesk
Olema Oncology announced interim results from its Phase 1b/2 Palazestrant study, showing an 85% clinical benefit rate across all CBR-eligible patients.
May 15, 2024 | 11:12 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Oncology announced interim results from its Phase 1b/2 Palazestrant study, showing an 85% clinical benefit rate across all CBR-eligible patients. This positive outcome could boost investor confidence and potentially drive the stock price up in the short term.
The high clinical benefit rate of 85% in the interim results of the Phase 1b/2 Palazestrant study is a significant positive indicator for Olema Oncology. This could lead to increased investor confidence and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100